Lupus may be a disease involving only the skin or it can be more generalized with major immune dysfunction resulting in systemic changes to the kidneys, bone marrow, joints, brain, gastrointestinal tract and heart.
Some patients may get partial palliative improvement with a number of existing treatments. However, if lupus continues to progress despite these therapies, the introduction of stem cells and specific immunotherapies may result in a profound improvement.
Stem Cell Genetic Med requests medical records including specialist summaries, laboratory tests and x-ray/MRI results. Results of antibody tests including ANA, topisomerase antibody, anticentromere antibody, anti-ThRNP, anti-PM-Sci, anti-U3 RNP, antiendothelial cell (AECA), anti-Fibrillin (FBN1), anti-platelet derived growth factor, anti-MMP-3, and anti-matrix metalloproteinase (MMP) are requested or should be ordered to complete medical evaluation.
Treatment will vary with each patient depending on involvement of single or multiple organs. Stem Cell Genetic Med has two effective forms of treatment in dealing with this disabling autoimmune disorder:
- The use of autologous (self) stem cells derived from the patient’s own peripheral blood or bone marrow.
- The use of stem cells derived from umbilical cord blood and then administered intravenously into the patient. Umbilical cord blood stem cells are far more potent as compared to adult autologous stem cells. A combination of progenitor CD 34+ and CD 133+ cells, dendritic immune cells, stem cell growth factor, and G-CSF are given intravenously.
- Anti-TGF beta one (transforming growth factor beta) to reduce or prevent skin and/orlung fibrosis, anti-IL6 to reduce inflammation and fibrosis, activator protein-1 (AP-1), antifibroblast antibodies and imatinib (Glivec) that reduce fibroblasts.